Lachesis Biosciences
  • HOME
  • ABOUT
    • Expertise
    • Team
  • Rivamist-Lead Candidate
  • INVESTORS
    • Financial Reports
    • News & Presentations

Rivamist 

Picture
Our patented rivastigmine nasal spray has the potential to improve the efficacy, tolerability and convenience of this class of drugs known as cholinesterase inhibitors.

First human study of nasal absorption of a cholinesterase inhibitor (rivastigmine)
  • Rivamist provides a therapeutically effective blood levels of rivastigmine (graph below).
  • Rivamist produces low NAP226-90 metabolite levels which helps reduce gastrointestinal side effects.​​

Initial clinical trial results

Picture

​Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516   PMID: 27639640   DOI: 10.1111/bcp.13133   ANZCTR reference: ACTRN12614001313628

Other opportunities

Organophosphorus poisoning treatment
Existing nerve agent antidotes lack sufficient entry to brain so soldiers may be at-risk of post-exposure seizures and neuronal damage. Rivastigmine readily enters the brain so it has potential to treat and/or prevent organophosphorus poisoning.

Important note: All the drug candidates above are not yet approved by any regulatory agency for commercial sale and use in humans in any country, territory or jurisdiction.
Contact
Terms of Use
​Privacy
© COPYRIGHT LACHESIS BIOSCIENCES LTD 2025. ALL RIGHTS RESERVED.
  • HOME
  • ABOUT
    • Expertise
    • Team
  • Rivamist-Lead Candidate
  • INVESTORS
    • Financial Reports
    • News & Presentations